Overview
AUPH market data
Price History
AUPH price chart
Valuation & Profitability
- P/E (TTM)
- 6.67 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.07 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.61 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 100.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $10.34 – $19.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2B · P/B 3.62 · P/S 6.67.
Company News
RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16Benzinga · Aug 7, 2026, 6:32 PM
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M EstBenzinga · Aug 6, 2026, 12:41 PM
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M EstimateBenzinga · Aug 6, 2026, 12:41 PM
8-K filing — Aurinia Pharmaceuticals Inc. (AUPH)SEC EDGAR · Aug 6, 2026, 12:03 PM
Aurinia Pharmaceuticals' New Analysis Of Aurora 1 Phase 3 Study Of Lupkynis For Lupus Nephritis Shows Statistically Significant 53% Reduction In The Risk Of Renal-related Event Or DeathBenzinga · Jun 4, 2026, 11:15 AM